L-(+)-Ergothioneine
(Synonyms: 麦角硫因; L-(+)-Ergothioneine) 目录号 : GC44019
L-(+)-Ergothioneine是一种含硫的组氨酸衍生物,是一种有效的抗氧化剂。
Cas No.:497-30-3
Sample solution is provided at 25 µL, 10mM.
L-(+)-Ergothioneine, a sulfur-containing histidine derivative, is an effective antioxidant[1].
In vitro, L-(+)-Ergothioneine (100μM; 18h) protects RPE cell from Sodium iodate (SI)-induced apoptotic and necrotic cell death in vitro[2]. L-(+)-Ergothioneine (10mM; 24h) modulates the tumor microenvironment to facilitate adjuvant vaccine immunotherapy[3].
In vivo, L-(+)-Ergothioneine (35mg/kg; 7 weeks; p.o.) and L-(+)-Ergothioneine’s combination with metformin attenuates renal dysfunction in type-2 diabetic rat model by activating Nrf2 antioxidant pathway[4]. The antioxidant L-(+)-Ergothioneine (15 and 60mg/kg; 30 days) prevents cystine lithiasis in the Slc7a9-/- mouse model of cystinuria[5]. The supplementation of L-(+)-ergothioneine (70mg/kg; 7 days; p.o.) can protect the livers and kidneys of mice from lipid peroxidation damage caused by ferric-nitrilotriacetate (Fenton reagent)[6].
References:
[1] Chen L, Zhang L, Ye X, Deng Z, Zhao C. Ergothioneine and its congeners: anti-ageing mechanisms and pharmacophore biosynthesis. Protein Cell. 2024 Feb 29;15(3):191-206.
[2] Gu S, Wu S, Lin Z, Han Z, Mo K, Huang H, Li M, Li G, Ouyang H, Wang L. Screening and evaluation of antioxidants for retinal pigment epithelial cell protection: L-ergothioneine as a novel therapeutic candidate through NRF2 activation. Exp Eye Res. 2024 May;242:109862.
[3] Yoshida S, Shime H, Matsumoto M, Kasahara M, Seya T. Anti-oxidative Amino Acid L-ergothioneine Modulates the Tumor Microenvironment to Facilitate Adjuvant Vaccine Immunotherapy. Front Immunol. 2019 Apr 4;10:671.
[4] Dare A, Channa ML, Nadar A. L-ergothioneine and its combination with metformin attenuates renal dysfunction in type-2 diabetic rat model by activating Nrf2 antioxidant pathway. Biomed Pharmacother. 2021 Sep;141:111921.
[5] Mayayo-Vallverdú C, López de Heredia M, Prat E, González L, Espino Guarch M, Vilches C, Muñoz L, Asensi MA, Serra C, Llebaria A, Casado M, Artuch R, Garrabou G, Garcia-Roves PM, Pallardó FV, Nunes V. The antioxidant l-Ergothioneine prevents cystine lithiasis in the Slc7a9-/- mouse model of cystinuria. Redox Biol. 2023 Aug;64:102801.
[6] Deiana M, Rosa A, Casu V, Piga R, Assunta Dessì M, Aruoma OI. L-ergothioneine modulates oxidative damage in the kidney and liver of rats in vivo: studies upon the profile of polyunsaturated fatty acids. Clin Nutr. 2004 Apr;23(2):183-93.
L-(+)-Ergothioneine是一种含硫的组氨酸衍生物,是一种有效的抗氧化剂[1]。
在体外,L-(+)-Ergothioneine (100μM; 18小时)可保护RPE细胞免受碘酸钠(SI)诱导的凋亡和坏死性细胞死亡[2]。L-(+)-Ergothioneine (10mM; 24小时)能够调节肿瘤微环境,从而促进辅助疫苗免疫疗法[3]。
在体内,L-(+)-Ergothioneine (35mg/kg; 7周; 口服)及其与二甲双胍的联合使用可通过激活Nrf2抗氧化途径减轻2型糖尿病大鼠模型的肾功能障碍[4]。抗氧化剂L-(+)-Ergothioneine (15和60mg/kg; 30天)可预防Slc7a9-/-小鼠模型中的胱氨酸尿症导致的胱氨酸结石[5]。L-(+)-Ergothioneine (70mg/kg; 7天; 口服)的补充可保护小鼠肝脏和肾脏免受由铁 - 三乙酸铁(Fenton试剂)引起的脂质过氧化损伤[6]。
Cell experiment [1]: | |
Cell lines | human RPE cells |
Preparation Method | hRPE cells treated with L-(+)-Ergothioneine (100μM) and/or SI for 18h. After being seeded and grown in a conditioned medium, the cells were washed and subsequently collected through centrifugation to prepare for Annexin V-FITC/PI staining. The pellet obtained from each well was dissolved again in 500μL of binding buffer. Afterwards, each sample was mixed with 5μL of FITC and 5μL of PI, followed by an incubation at 37°C for 15min. Flow cytometry was used with the BD LSRFortessa™ cell analyzer from the United States to determine apoptotic proportions. |
Reaction Conditions | 100μM; 18h |
Applications | L-(+)-Ergothioneine protects RPE cell from SI-induced apoptotic and necrotic cell death in vitro. |
Animal experiment [2]: | |
Animal models | Thirty-six (36) adult male Sprague-Dawley rats |
Preparation Method | After the induction of diabetes, non-diabetic rats were subdivided into two groups, and the diabetic rats were randomly divided into four groups (n = 6) and treated as follows: Non-diabetic control (NC)-1ml/100g bwt of distilled water; Diabetes control (DC)-1ml/100g bwt of distilled water; Diabetes + L-(+)-Ergothioneine (DE)-35mg/kg bwt of L-(+)-Ergothioneine; Diabetes + metformin (DM)-500mg/kg bwt of metformin; Diabetes + L-(+)-Ergothioneine + metformin (DEM). Distilled water, L-(+)-Ergothioneine and metformin were administered orally for seven weeks after confirmation of diabetes. In addition, body weight was recorded every week. After seven weeks of treatment, the animals were placed individually in a metabolic cage for 24h to measure water intake and collect urine samples using a sterile container. Urine volume was recorded, and the collected samples were centrifuged at 2000rpm, 10min at 4°C to remove any suspended particles. The urine samples were then aliquoted in Eppendorf tubes and stored at -20°C until analysis. Rats were sacrificed by decapitation, and blood samples were collected into a serum vacutainer bottle; centrifuged at 3000rpm for 10min to obtain serum and stored in the bio-freezer at -80°C until used for analysis. The kidneys were rapidly excised, cleaned of adhering tissues, weighed, and rinsed in cold saline. The right kidney was rapidly frozen in liquid nitrogen and stored at -80°C until used for analysis, while the left kidney was fixed in 10% neutral-buffered formalin histopathological analysis. |
Dosage form | 35mg/kg; 7 weeks; p.o. |
Applications | L-(+)-Ergothioneine and L-(+)-Ergothioneine’s combination with metformin attenuates renal dysfunction in type-2 diabetic rat model by activating Nrf2 antioxidant pathway. |
References: |
Cas No. | 497-30-3 | SDF | |
别名 | 麦角硫因; L-(+)-Ergothioneine | ||
Canonical SMILES | C[N+](C)([C@@H](CC(N1)=CNC1=S)C([O-])=O)C | ||
分子式 | C9H15N3O2S | 分子量 | 229.3 |
溶解度 | PBS (pH 7.2): 10 mg/ml | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
![]() |
1 mg | 5 mg | 10 mg |
1 mM | 4.3611 mL | 21.8055 mL | 43.611 mL |
5 mM | 0.8722 mL | 4.3611 mL | 8.7222 mL |
10 mM | 0.4361 mL | 2.1805 mL | 4.3611 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet